Mubucho (Dasatinib)

Dasatinib, the active ingredient in Mubucho, is a tyrosine kinase inhibitor presented as an unknown/unknown for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Mubucho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Dasatinib is a targeted tyrosine‑kinase inhibitor used in hematologic malignancies that involve the BCR‑ABL fusion protein. - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival. - Chronic myeloid leukemia (accelerated or blast phase): provides disease control when resistance to first‑line therapy occurs. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: induces remission by inhibiting BCR‑ABL‑positive blasts.

Dasatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Fatigue: generalized tiredness. - Rash: skin erythema or pruritus. - Myelosuppression: reduced white blood cells, platelets, or neutrophils. - Fluid retention: peripheral edema.

Serious or Rare Side Effects: - Pleural effusion: accumulation of fluid around the lungs. - Pulmonary hypertension: elevated pressure in pulmonary arteries. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Cardiac dysfunction: decreased left‑ventricular ejection fraction. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe infections: opportunistic bacterial, fungal, or viral infections.

When prescribing Dasatinib, clinicians should observe several safety measures. - Monitor blood counts: perform complete blood count regularly to detect myelosuppression. - Assess cardiac function: baseline ECG and periodic monitoring for pulmonary hypertension. - Evaluate for pleural effusion: watch for dyspnea, cough, or chest discomfort. - Avoid strong CYP3A4 inhibitors: concomitant use may increase dasatinib exposure. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Dasatinib interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations. - Antacids containing aluminum or magnesium: reduce oral absorption of dasatinib. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): require dose adjustment. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower dasatinib levels and reduce effectiveness. - Warfarin: concurrent use may enhance anticoagulant effect and bleeding risk.